Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia
- 1 November 1993
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 67 (5), 205-211
- https://doi.org/10.1007/bf01715048
Abstract
It was the aim of this study to investigate the antileukemic activities of recombinant interferon beta (rIFN beta) in chronic-phase CML in vitro and in vivo. Nine patients in the early chronic-phase of CML were treated in a phase-II trial with escalating doses of rIFN beta. In parallel, antiproliferative and immunomodulatory activities of rIFN beta and rIFN alpha 2b were studied in vitro. rIFN beta exhibited a significantly higher antiproliferative activity on hematopoietic progenitor cells of CML patients in vitro than rIFN alpha 2b. In contrast, only very limited clinical antileukemic efficacy of rIFN beta was observed. None of the patients achieved a complete or partial hematologic response (0% response rate, 0–36% 95 C.I.). Primary resistance of CML patients to rIFN beta treatment was caused neither by antibody formation against the recombinant material nor by deficient IFN receptor targeting and/or signaling: Induction of serum levels of beta-2-microglobulin (Β-2-m) and neopterin after administration of rIFN beta was comparable to that seen after administration of rIFN alpha. However, rIFN beta treatment less effectively induced biosynthesis of interleukin-1 receptor antagonist protein (IL-1-Ra) than rIFN alpha 2b. Thus, we conclude that rIFN beta at doses up to 12 MU/day s.c. is ineffective for treatment of chronic-phase CML. Further investigations into divergent biologic responses to various type-I interferons might help to elucidate mechanisms crucial for IFN action in patients with CML.Keywords
This publication has 37 references indexed in Scilit:
- Rekombinantes Interferon α-2c bei Ph-positiver chronischer myeloischer Leukämie: Ergebnisse einer multizentrischen Phase-II-StudieDeutsche Medizinische Wochenschrift (1946), 1991
- Recombinant human interferon (IFN) alpha‐2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti‐interferon antibodiesBritish Journal of Haematology, 1989
- Interferon-beta induced remission in a hairy cell leukemia patient resistant to interferon-alphaLeukemia Research, 1988
- Cytokines in the Control of Beta-2 Microglobulin Release. I. In vitro Studies on Various Haemopoietic CellsImmunobiology, 1988
- IFN-β-Therapie bei der HaarzelleukämieJournal of Molecular Medicine, 1987
- Toxicity of interferon and interleukinTrends in Pharmacological Sciences, 1987
- MULTICENTRE DOUBLE-BLIND STUDY OF EFFECT OF INTRATHECALLY ADMINISTERED NATURAL HUMAN FIBROBLAST INTERFERON ON EXACERBATIONS OF MULTIPLE SCLEROSISThe Lancet, 1986
- Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous LeukemiaThe New England Journal of Medicine, 1986
- Myelopoiesis of human bone marrow cells in a micro‐agar culture system: Comparison of two sources of colony stimulating activity (CSA)The International Journal of Cell Cloning, 1983
- Interferon: pharmacokinetics and toxicityPhilosophical Transactions of the Royal Society of London. B, Biological Sciences, 1982